驱动力(920275) - 2025 Q4 - 年度业绩

Financial Performance - The company's operating revenue for the reporting period is expected to be CNY 76.81 million, a year-on-year increase of 7.07%[4] - The total profit is projected to be CNY 4.65 million, representing a significant decline of 69.32% compared to the previous year[4] - The net profit attributable to shareholders is expected to be CNY 4.55 million, down 67.42% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be CNY 4.43 million, a decrease of 64.00%[4] - The basic earnings per share are projected to be CNY 0.03, a decline of 67.42% compared to the previous year[4] Assets and Equity - The total assets at the end of the reporting period are estimated to be CNY 241.78 million, a decrease of 1.87% compared to the beginning of the period[4] - The equity attributable to shareholders is expected to be CNY 233.47 million, down 2.10% year-on-year[4] Operational Challenges - The decrease in net profit is primarily due to a shift in product sales, with higher-margin products' sales proportion dropping by approximately 18.45%[6] - The company experienced a significant increase in management expenses, approximately CNY 1.31 million, impacting overall profitability[7] Cautionary Note - The report emphasizes that the financial data is preliminary and has not been audited, urging investors to be cautious[10]

Guangdong Drive Bio-tech Group-驱动力(920275) - 2025 Q4 - 年度业绩 - Reportify